CD45 is a transmembrane cell surface glycoprotein expressed on almost all hematopoietic cells and absent on non-hematopoietic cells. CD45 is an abundantly expressed target in most hematologic malignancies, including 85-90% of cases of acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). Due to the stability of CD45 on the cell surface, it is an attractive candidate for antigen-specific immunotherapy and other targeted oncology approaches. This humanized anti-CD45 antibody has the potential to decrease infusion toxicities in some patients. Moreover, the humanized antibody limits anti-mouse antibody (HAMA) immunization leaving additional treatment options open for patients. Drs. Brenda Sandmaier and Roland Walter at Fred Hutch have developed chimeric and humanized forms of CD45 antibodies. Initial in vivo CD45+ cell targeting biodistribution studies show enrichment of radiolabeled antibody in immunodeficient mice xenotransplanted with human CD45+ leukemia cells.
Hematologic malignancies, including AML and ALL
Antibody can be used across modalities: antibody-drug conjugates, radioimmunotherapy, chimeric antigen receptors
Conditioning regimens for hematopoietic stem cell transplant
Toxicity and HAMA immunization seen in prior iteration murine antibody is reduced or eliminated
Adaptable across modalities & available in multimerized forms
CD45 is a clinically validated target
Provisional patent application
The global hematologic malignancies market size was valued at USD 35.6 billion in the year 2016 with a CAGR of 10.48%. Worldwide, more than 300,000 people are diagnosed with leukemia each year.
Brenda M. Sandmaier, MD - Professor, Clinical Research Division
Roland B. Walter, MD, PhD, MS - Professor, Clinical Research Division